Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Clodipan is a fixed-dose combination of candesartan cilexetil, an angiotensin II receptor blocker (ARB), and amlodipine, a dihydropyridine calcium channel blocker (CCB). It is approved for the treatment of hypertension (high blood pressure). Candesartan cilexetil is a prodrug that is hydrolyzed to candesartan, which selectively blocks the binding of angiotensin II to the AT1 receptor, leading to vasodilation and decreased aldosterone secretion. Amlodipine inhibits the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle, resulting in peripheral arterial vasodilation and reduced peripheral vascular resistance. Together, these complementary mechanisms provide synergistic blood pressure reduction and organoprotective effects.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on candesartan cilexetil + amlodipine.